Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
Gavin Giovannoni(Queen Mary University of London), Gilmore O’Neill(Biogen (United States)), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), Lakshmi Amaravadi(Takeda (United States)), Ernst‐Wilhelm Radue, Ralf Gold(St. Josef-Hospital), Marianne T. Sweetser(Alnylam Pharmaceuticals (United States)), Eva Havrdová(Charles University), Manjit McNeill(Biogen (United States)), Jacob Elkins(Biogen (United States)), Dusan Stefoski(Rush University Medical Center), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya)
Cited by 94
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k